Epithalon vs Pinealon
Epithalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), derived from the pineal extract preparation Epithalamin. Pinealon is the synthetic tripeptide Glu-Asp-Arg (EDR). Both came out of the same programme at the St Petersburg Institute of Bioregulation and Gerontology, both are described in that literature as ultrashort peptide bioregulators acting on gene expression, and the shared pineal association in their names is why they are so often set side by side. Unusually for this category, direct evidence exists: seven published experiments applied both peptides within a single design, covering rat pineal organ culture, induced neurons from elderly human donors, hypobaric hypoxia in vivo, nuclear penetration in HeLa cells and histone binding in vitro. Every one of those experiments comes from the same institute and its collaborators, none was conducted in humans, and the results diverge by endpoint rather than favouring one peptide consistently.
They have been compared directly.
Seven located studies applied both AEDG and EDR inside one experimental design, and where the two separate the winner changes with the endpoint. In the 2008 hypobaric hypoxia work, all four short peptides tested showed antihypoxic properties and pinealon had the most pronounced effect of them. In the companion in vitro paper from the same year, none of the peptides had direct antioxidant activity and all raised the stationary level of intracellular reactive oxygen species, but every peptide except epitalon reduced the fraction of dead cells in a neuronal population. In the 2024 induced-neuron model built from elderly donor fibroblasts, all three peptides tested increased dendritic arborisation, while the reduction in oxidative DNA damage was attributed specifically to EDR. In the 2025 senescence study using the same transdifferentiation approach, the fall in p21 and beta-galactosidase activity was credited to AEDG and KED, with EDR tested but not credited. In rat pineal organ culture, AEDG stimulated Ki-67 and was the only peptide to stimulate pinealocyte CGRP synthesis, while EDR did neither. The two biophysical papers are not efficacy studies at all: labelled epithalon and pinealon both entered HeLa nuclei and both bound CNG- and CAG-containing oligonucleotides, and both bound wheat histones in a site-specific manner. No study compared the peptides in a whole animal outside the hypoxia model, and no human study has compared them.
The 11 studies that tested both
- 01In vitro2025
The Influence of Short Peptides on Cell Senescence and Neuronal Differentiation
Sakhenberg E, et al. · Curr Issues Mol Biol · transdifferentiation of fetal mesenchymal stem cells into induced cortical neurons using microRNAs, transcription factors and small molecules, with KED, EDR and AEDG peptides applied at the end of the process
AEDG and KED applied at the end of transdifferentiation decreased expression of the cell cycle marker p21 and reduced beta-galactosidase activity. EDR was tested in the same design but was not credited with those reductions. None of the peptides altered TUj-1 or LaminB1 expression.
- 02In vitro2024
Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes
Kraskovskaya N, et al. · Int J Mol Sci · human neuronal ageing model based on transdifferentiation of dermal fibroblasts from elderly donors into induced cortical neurons, with EDR, KED and AEDG peptides
All three peptides promoted arborisation of the dendritic tree, increasing both the number of primary processes and total dendrite length. EDR specifically reduced oxidative DNA damage in induced neurons from elderly donors, an effect not attributed to AEDG. None of the peptides affected mitochondrial or lysosomal activity or p16 levels.
- 03In vitro2013
Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides
Fedoreyeva LI, et al. · Biochemistry (Mosc) · fluorescence quenching assays of six short peptides, including Ala-Glu-Asp-Gly and Glu-Asp-Arg, against FITC-labelled wheat histones H1, H2B, H3 and H4 and their complexes with deoxyribooligonucleotides
Both peptides bound the labelled histones, with binding attributed to interaction with N-terminal histone regions. Binding depended on the histone involved and on the primary structures of the peptide and the oligonucleotide, and was therefore described as site specific. The authors suggested that such interactions could act as epigenetic control mechanisms in chromatin.
- 04In vitro2011
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA
Fedoreyeva LI, et al. · Biochemistry (Mosc) · HeLa cells incubated with fluorescein isothiocyanate-labelled epithalon, pinealon and testagen, with Stern-Volmer analysis of binding to labelled single- and double-stranded deoxyribooligonucleotides and DNA
Labelled epithalon and pinealon both produced marked fluorescence in cytoplasm, nucleus and nucleolus, so both entered the nucleus. Both bound preferentially to oligonucleotides containing CNG sequences and, along with testagen, appeared to prefer CAG-containing sequences, while bronchogen preferred CTG. The quenching constants differed between peptides, which the authors read as sequence-specific interaction.
- 05In vitro2011
Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture
Khavinson VKh, et al. · Bull Exp Biol Med · organotypic culture of pineal gland from 3-month-old rats treated with Ala-Glu-Asp-Gly, Lys-Glu-Asp, Glu-Asp-Arg and Lys-Glu
Ala-Glu-Asp-Gly and Lys-Glu-Asp stimulated expression of the proliferative protein Ki-67, and synthesis of CGRP by pinealocytes was stimulated only by Ala-Glu-Asp-Gly. Glu-Asp-Arg did not produce either effect, and none of the peptides altered expression of the apoptosis marker AIF. This is the one experiment in pineal tissue itself in which both peptides were applied.
- 06Animal in vivo2008· Russian (English abstract)
[Investigation of antihypoxic properties of short peptides]
Kozina LS · Adv Gerontol · hypobaric hypoxia model comparing vilon, epitalon, vesugen and pinealon, with supporting experiments on prenatal hypoxia and neuronal resistance
All four short peptides showed antihypoxic properties in the hypobaric hypoxia model, and pinealon had the most pronounced effect of the four. The author attributed pinealon's protection less to suppression of the stress-induced rise in reactive oxygen species than to stimulation of intrinsic antioxidant enzymes and possible limitation of N-methyl-D-aspartate excitotoxicity.
- 07In vitro2008· Russian (English abstract)
[Biological activity of regulatory peptides in model experiments in vitro]
Kozina LS, et al. · Adv Gerontol · in vitro model experiments with pinealon, vesugen, vilon and epitalon on human lipoprotein peroxidation, erythrocyte membrane stability and a neuronal cell population
None of the four peptides showed direct antioxidant activity, although all restricted lipid peroxidation of human lipoproteins by modifying their structure and increased erythrocyte membrane stability against osmotic haemolysis. All raised the stationary level of intracellular reactive oxygen species, and all except epitalon decreased the percentage of dead cells in the neuronal population.
- 08In vitro2023
Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters
Khavinson VK, et al. · Biomolecules · molecular modelling and computer-assisted docking of 26 ultrashort peptides, including AEDG and EDR, against the LAT1, LAT2 and PEPT1 transporters, benchmarked against all 8400 di- and tripeptides
The 26 peptides bound the modelled transporters more efficiently than di- and tripeptides of unestablished activity, and EDR was among the ligands identified as most effective. AEDG appeared in the subset whose reported antitumour effect the authors speculated might involve transporter inhibition. The work is computational and no peptide was administered.
- 09Review2016
Short Peptides and Telomere Length Regulator Hormone Irisin
Khavinson VKh, et al. · Bull Exp Biol Med · short communication on irisin and the epigenetic regulation of its expression by Lys-Glu, Glu-Asp-Arg and Ala-Glu-Asp-Gly
The paper discussed all three peptides in relation to irisin, a muscle-derived hormone described as inducing telomere elongation in normal somatic cells. It concluded that Lys-Glu and Glu-Asp-Arg modulate lifespan by modulating irisin gene expression, and did not attribute that effect to Ala-Glu-Asp-Gly.
- 10Review2021· Russian (English abstract)
[Epigenetic regulation of adaptogenesis by pathology and aging.]
Rubinskii AV, et al. · Adv Gerontol · review of adaptation to internal and external factors in pathology and ageing, framed around the hypothalamic-pituitary-pineal and hypothalamic-pituitary-thymic axes
The review listed AEDG and EDR alongside AEDP, KED, EW and KE as epigenetic regulators of gene expression and protein synthesis said to participate in the stress response and in activation of those axes. Both peptides are named as members of one class rather than compared, and no experiment is reported.
- 11Review2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, et al. · J Am Acad Orthop Surg Glob Res Rev · narrative review of therapeutic peptides in orthopaedic practice, grouped by proposed signalling mechanism
The review grouped epithalon, delta sleep-inducing peptide and pinealon together as recovery-enhancing agents said to target circadian and mitochondrial regulators. It stated that preclinical studies are promising but that clinical trials are currently lacking, and reported no experiment involving either peptide.
Side by side.
| Epithalon | Pinealon | |
|---|---|---|
| Evidence maturity | Early clinical | Preclinical only |
| Studies cited here | 15 | 18 |
| Published 2023 or later | 8 | 3 |
| Newest paper | 2026 | 2024 |
| Sequence and origin | The tetrapeptide Ala-Glu-Asp-Gly, designed as a defined single-sequence analogue of Epithalamin, a pineal-gland polypeptide extract that had been the subject of Soviet and Russian gerontology research since the 1970s. | The tripeptide Glu-Asp-Arg, one of the short peptide bioregulators from the same programme. It is frequently misdescribed elsewhere as a dipeptide; the published literature consistently gives three residues, and the trade name derives from the organotypic pineal culture model rather than from a pineal extract. |
| Mechanism as described in the literature | Induction of telomerase activity and telomere elongation in cultured human somatic cells, together with modulation of circadian and pineal gene expression, antioxidant effects and proposed binding to histones and DNA on molecular modelling. | An epigenetic mechanism throughout: entry into the nucleus, binding to specific double-stranded DNA sequences and histone proteins, and consequent modulation of genes for apoptosis, antioxidant defence and neuroplasticity. Physical support comes from spectroscopy and molecular dynamics of EDR-DNA binding rather than from in vivo target engagement. |
| Size and character of the evidence base | The larger of the two, spanning cell culture, Drosophila, rodents, aged rhesus monkeys and human reports, with a 2025 narrative review covering roughly 25 years of literature and a 2026 review placing it among investigational geroprotective peptides. | Smaller and narrower. Almost entirely in vitro or rodent work from one research group, supplemented by molecular-modelling studies, with the human record limited to occupational and geriatric studies of peptide combinations rather than EDR alone. |
| Best-characterised finding | Telomerase induction and telomere elongation in human fetal fibroblast cultures at the Hayflick limit, first reported in 2003 and the foundation of every subsequent telomere claim. A 2025 study from an independent group reported increased telomere length in human cell lines. | Dose-dependent restriction of reactive oxygen species accumulation and reduced necrotic cell death in cerebellar granule cells, neutrophils and PC12 cells under oxidative stress, reported in 2011, with delayed ERK1/2 activation and cell-cycle modification. |
| Human data | Present but weak. A buccal epithelium study reported reduced p16, p21 and p53 expression in subjects with disturbed melatonin secretion, and a 6- to 8-year follow-up of 266 elderly subjects reported reduced mortality, but that report was open and non-randomised and used the Epithalamin extract rather than the synthetic tetrapeptide. | Weaker still. The principal report is an occupational study of 150 lorry drivers against 150 controls in which bioregulating peptides were said to improve psychoemotional indices, with the best effect from pinealon combined with vezugen. Pinealon was not tested alone and the design was not placebo-controlled. |
| Evidence maturity | Early clinical: human reports exist, but none is a registered, randomised, placebo-controlled trial of the synthetic tetrapeptide, and the human longevity data concern the extract preparation. | Preclinical only: there is no randomised, placebo-controlled trial of EDR alone in humans, no pharmacokinetic data, and no demonstration that administered EDR reaches brain tissue intact. |
| Recency of primary research | Active. Primary in vitro studies appeared in 2022, 2025 and 2026 in retinal pigment epithelial cells, bovine and mouse oocytes and human cell lines, several of them from groups outside the originating institute. | Largely confined to the originating network. The most recent primary work naming EDR is the shared short-peptide neuronal series of 2024 and 2025, in which EDR is one arm among several, and a 2023 computational transport study. |
| Independent replication, safety and regulatory status | Some independent in vitro replication since 2022, but no independent in vivo work. Neither human pharmacokinetics, dose-response nor long-term safety has been characterised, including any oncological question raised by telomerase induction, and no formulation is approved in any jurisdiction. | Independent replication outside the St Petersburg group is effectively absent, and the central epigenetic mechanism rests on docking and in vitro binding. No safety, pharmacokinetic or regulatory record exists, and no formulation is approved in any jurisdiction. |
And what it does not.
This is one of the few pairs in this category with genuine head-to-head data, and the data do not produce a winner. Across seven experiments that applied both peptides, EDR led on antihypoxic effect in vivo and on reduction of oxidative DNA damage in aged induced neurons, AEDG led on pinealocyte proliferative and secretory activity and on senescence markers during neuronal transdifferentiation, and in one in vitro model epitalon was the only peptide that failed to reduce the dead-cell fraction. The two biophysical studies found both peptides entering nuclei and binding the same classes of sequence, which supports a shared mechanism rather than a ranking. Every one of these experiments originates from the same institute and its collaborators, all were conducted in cells, rodents or cell-free systems, and none was randomised or blinded. Away from the shared experiments, Epithalon has the larger literature and the only independent replication, while Pinealon's record is thinner and almost wholly in-house. Neither has controlled human evidence for any outcome.
Common questions.
- Which published experiments applied both peptides within the same design?
Seven. Two 2008 Russian studies tested pinealon and epitalon alongside vilon and vesugen, one in hypobaric hypoxia in vivo and one in vitro. A 2011 study applied both to rat pineal organ culture. Two biophysical papers, from 2011 and 2013, examined nuclear penetration in HeLa cells and binding to wheat histones. A 2024 study used induced neurons from elderly donor fibroblasts, and a 2025 study used mesenchymal stem cells transdifferentiated into neurons.
- Did either peptide outperform the other where both were tested?
Neither did so consistently. Pinealon had the most pronounced antihypoxic effect of four peptides in the hypobaric hypoxia model, and the reduction in oxidative DNA damage in aged induced neurons was attributed to EDR alone. AEDG was the only peptide to stimulate pinealocyte CGRP synthesis in pineal organ culture and was credited, with KED, for the fall in p21 and beta-galactosidase activity during neuronal transdifferentiation. In one in vitro model epitalon was the single peptide that did not reduce the dead-cell fraction.
- Is Pinealon a dipeptide or a tripeptide?
A tripeptide. The published literature gives Pinealon as Glu-Asp-Arg, abbreviated EDR, throughout: the fluorescence work labels it as such, the DNA-binding studies model three residues, and the transporter docking study lists EDR among tripeptides. Descriptions of it as a two-residue Glu-Asp peptide appear on some commercial pages but do not match any indexed publication. The distinction matters because the arginine residue is what carries the positive charge in the proposed peptide-DNA interaction.
- Do the nuclear-penetration studies show that either peptide reaches its target in a living body?
No. The 2011 HeLa study showed that fluorescently labelled epithalon and pinealon entered the cytoplasm, nucleus and nucleolus of cultured cells, and the binding assays showed sequence-preferential interaction with oligonucleotides and DNA in cell-free conditions. Both are in vitro observations. No published work has demonstrated that either peptide, administered to an animal or a person, reaches nuclei in target tissue intact and at concentrations comparable with those used in culture.
- Has either peptide been tested in a registered randomised trial in humans?
Neither has. For Epithalon, the human longevity report followed 266 elderly subjects over six to eight years in an open, non-randomised design and used the Epithalamin pineal extract rather than the synthetic tetrapeptide; a separate buccal epithelium study reported changes in senescence-associated proteins. For Pinealon, the principal human report is a non-placebo-controlled occupational study of lorry drivers in which the peptide was given in combination with vezugen and never alone.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.